Affinity Asset Advisors, LLC

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.

Issuer % of Class Filed
Lexeo Therapeutics, Inc. 13G/A
LXEO · 52886X107
 8.4% 8/13/2026
Event 6/30/2026
Equillium Inc. 13G
EQ · 29446K106
 6.5% 8/13/2026
Event 6/30/2026
Amanat Acquisition Corp. 13G
AMAN · G0375M101
 5.0% 8/13/2026
Event 6/30/2026
First Tracks Biotherapeutics, Inc 13G
TRAX · 337185102
 5.8% 8/13/2026
Event 6/30/2026
Forte Biosciences, Inc. 13G/A
FBRX · 34962G208
 5.6% 8/13/2026
Event 6/30/2026
Ovid Therapeutics Inc. 13G/A
OVID · 690469101
 7.9% 8/13/2026
Event 6/30/2026
Avalo Therapeutics, Inc. 13G/A
AVTX · 05338F306
 5.5% 8/13/2026
Event 6/30/2026
iBio, Inc. 13G/A
IBIO · 451033708
 10.0% 8/13/2026
Event 6/30/2026
NextCure, Inc. 13G/A
NXTC · 65343E207
 6.4% 8/13/2026
Event 6/30/2026
Ventyx Bioscience, Inc. 13G/A
VTYX · 92332V107
 0% 5/14/2026
Event 3/31/2026
Sutro Biopharma, Inc. 13G/A
STRO · 869367201
 6.5% 5/14/2026
Event 3/31/2026
Helix Acquisition Corp. III 13G
HLXC · G4444S107
 7.0% 5/14/2026
Event 3/31/2026
Karyopharm Therapeutics Inc. 13G/A
KPTI · 48576U205
 8.6% 5/14/2026
Event 3/31/2026
Verrica Pharmaceuticals Inc. 13G/A
VRCA · 92511W207
 5.5% 1/29/2026
Event 1/22/2026
Sutro Biopharma, Inc. 13G
STRO · 869367102
Amended under CUSIP 869367201 on 1/29/2026
7.8% 10/23/2025
Event 10/16/2025
Inozyme Pharma, Inc. 13G/A
INZY · 45790W108
 2.9% 5/30/2025
Event 5/20/2025